|
Fatty Liver
|
0.080 |
Biomarker
|
disease |
BEFREE |
The fatty liver index (FLI), which is calculated by the equation comprising waist circumference, body mass index (BMI), triglyceride, and gamma glutamyl transpeptidase (GGT), is frequently used for hepatic steatosis evaluation.
|
30981560 |
2020 |
|
Fatty Liver
|
0.080 |
Biomarker
|
disease |
BEFREE |
High BMI (OR = 1.369, P < .001), high diastolic blood pressure (OR = 1.048, P < .001), and high gamma glutamyl transpeptidase (OR = 1.018, P = .009) were independent risk factors for liver steatosis among T2DM patients.This study suggested risk factors screening of liver fibrosis and steatosis.
|
30212992 |
2018 |
|
Fatty Liver
|
0.080 |
Biomarker
|
disease |
BEFREE |
Univariate analysis revealed that higher age, female, lower body mass index (BMI), higher serum albumin, lower alanine aminotransferase (ALT), lower gamma-glutamyl transpeptidase, lower total bilirubin, lower α-fetoprotein, lower skeletal muscle attenuation, and liver steatosis were significantly associated with skeletal muscle volume loss.
|
29486094 |
2018 |
|
Fatty Liver
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Rs12979860 TT or rs8099917 GG genotypes as well as markers of serum and hepatocyte iron overload associated with higher activity of gamma-glutamyl transpeptidase and liver steatosis.
|
27125837 |
2017 |
|
Fatty Liver
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
Ezetimibe significantly reduced serum aspartate aminotransferase, alanine aminotransferase, and γ-glutamyl transpeptidase levels, and hepatic steatosis and hepatocyte ballooning.
|
28257594 |
2017 |
|
Fatty Liver
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Carriers of the rare CPT1b 66V (rs3213445) allele had significantly higher γ-glutamyl transpeptidase (GGT), glutamic oxaloacetic transaminase (GOT) and glutamic pyruvate transaminase (GPT) activities (P< 0·0001, P= 0·03 and P= 0·048, respectively) and a higher fatty liver index (FLI, P= 0·026).
|
22809552 |
2013 |
|
Fatty Liver
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Moreover, coreMM was associated with a higher γ-glutamyl transpeptidase level (P=0.026) as well as more severe liver fibrosis (P=0.027) than coreWW, and patients with aa70 substitution (coreMW) were associated with more severe liver steatosis and fibrosis than those without (P=0.020 and P=0.002, respectively).
|
21447872 |
2011 |
|
Fatty Liver
|
0.080 |
Biomarker
|
disease |
BEFREE |
Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins.
|
20537997 |
2010 |